ECOR
electroCore, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
10.52
▲ 0.31 (3.04%)
MARKET · —
Price
Open
10.15
Prev close
10.21
Day high
10.95
Day low
10.00
Volume
59.93K
Market cap
$94.85M
P/E (TTM)
—
52W range
4.41 – 10.95
Trailing performance
Returnvs SPY
1W
+5.52%
+6.9%
1M
+65.28%
+61.5%
3M
+75.63%
+72.5%
6M
+68.32%
+57.3%
YTD
+134.56%
+122.3%
1Y
+101.92%
+81.9%
3Y
+120.55%
+46.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$94.85M
Enterprise value$94.37M
Revenue (TTM)$36.97M
Gross profit$32.18M
EBITDA$-13.66M
Net income$-14.77M
EPS (TTM)$-1.65
Free cash flow$-4.68M
Total cash$10.04M
Total debt$9.56M
Book value / share$-0.31
Shares outstanding9.02M
Float5.96M
Short % of float4.09%
Dividend yield—
Beta (5Y)0.94
Valuation & profitability ratios
Trailing P/E—
Forward P/E-19.13
PEG ratio—
Price / sales—
Price / book—
EV / revenue2.55
EV / EBITDA-6.91
Gross margin87.06%
Operating margin-29.33%
Profit margin-39.96%
Return on equity—
Return on assets-55.00%
Debt / equity—
Current ratio1.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $32.03M | $25.18M | $16.03M | $8.59M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$13.97M | -$11.89M | -$18.83M | -$22.16M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$13.97M | -$11.89M | -$18.83M | -$22.16M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.42 | -0.33 | +21.8% |
| Mar 2026 | -0.61 | -0.59 | +3.7% |
| Dec 2025 | -0.39 | -0.34 | +13.4% |
| Sep 2025 | -0.40 | -0.40 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.28 | 4 | $11.11M | +27.8% |
| Next quarter | -0.23 | 4 | $11.86M | +28.3% |
| Current year | -1.40 | 5 | $41.92M | +30.9% |
| Next year | -0.46 | 4 | $54.37M | +29.7% |
Analyst targets & ownership
Mean target$19.57
High target$26.00
Low target$12.00
Implied upside86.03%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy1 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders32.45%
Held by institutions11.64%
Institutions holding38
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+66.32K
Net buying
Buy transactions
5
172.06K shares
Sell transactions
4
105.74K shares
Net transactions
+9
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
2.93M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 13, 26 | ERRICO THOMAS J. Director |
BUY | 5.00K | $49.27K | Direct |
| May 28, 26 | LEV JOSHUA S. President |
SELL | 6.67K | $60.00K | Direct |
| May 22, 26 | LEV JOSHUA S. President |
SELL | 3.00K | $19.50K | Direct |
| May 21, 26 | ERRICO THOMAS J. Director |
BUY | 10.00K | $59.90K | Direct |
| Apr 23, 26 | GOLDBERGER DANIEL S Former |
SELL | 80.00K | $544.00K | Direct |
| Apr 13, 26 | FOX MICHAEL Chief Operating Officer |
STOCK | 70.00K | $0 | Direct |
| Apr 10, 26 | GOLDBERGER DANIEL S Former |
SELL | 16.07K | $96.75K | Direct |
| Apr 1, 26 | LEV JOSHUA S. Chief Executive Officer |
STOCK | 45.00K | $0 | Direct |
| Mar 19, 26 | ERRICO THOMAS J. Director |
CONVERSION | 42.05K | $222.98K | Direct |
| Jan 26, 26 | LEV JOSHUA S. Chief Financial Officer |
STOCK | 27.89K | $0 | Direct |
| Jan 26, 26 | GOLDBERGER DANIEL S Chief Executive Officer |
STOCK | 46.38K | $152.20K | Direct |
| Dec 4, 25 | LEV JOSHUA S. Chief Financial Officer |
SELL | 2.50K | $12.63K | Direct |
| Dec 2, 25 | GOLDBERGER DANIEL S Chief Executive Officer |
BUY | 1.00K | $4.84K | Direct |
| Nov 12, 25 | LEV JOSHUA S. Chief Financial Officer |
SELL | 2.17K | $13.39K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BONFIGLIOLI ELENA |
Director | 30.55K | Stock Award(Grant) |
ERRICO THOMAS J. |
Director | 343.33K | Purchase |
FOX MICHAEL |
Chief Operating Officer | 70.00K | Stock Award(Grant) |
GANDOLFO JOHN P |
Director | 88.10K | Stock Award(Grant) |
GOLDBERGER DANIEL S |
Former | 211.47K | Sale |
GOLDSTEIN JULIE ANN |
Director | 101.39K | Stock Award(Grant) |
LEV JOSHUA S. |
President | 84.89K | Sale |
PATTON THOMAS M |
Director | 102.78K | Stock Award(Grant) |
THEOFILOS CHARLES STEVE |
Director | 622.86K | Stock Award(Grant) |
WILBER PATRICIA |
Director | 72.33K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
9.95
+5.78% from price
SMA 20
8.18
+28.55% from price
SMA 50
7.79
+35.02% from price
SMA 100
7.47
+40.74% from price
SMA 200
6.66
+57.85% from price
EMA 12
9.50
+10.74% from price
EMA 26
8.52
+23.41% from price
EMA 50
8.00
+31.45% from price
RSI (14)
73.4
Overbought
MACD (12,26,9)
0.98
Hist 0.30
ATR (14)
0.98
9.35% of price
Realised vol 30D
75.4%
Annualised
Bollinger upper
11.89
20, 2σ
Bollinger lower
4.47
20, 2σ
50 / 200 cross
Golden
7.79 vs 6.66
Trend bias
Above 200
+57.85%
Risk profile
Beta vs SPY
1.87
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
75.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-44.2%
Peak to trough
Max drawdown 5Y
-82.1%
Peak to trough
ATR 14
0.98
9.35% of price
Beta (reported)
0.94
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
electroCore Q2 Earnings Call Highlights
MarketBeat · 16d ago
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 16d ago
electroCore Announces Second Quarter 2026 Financial Results
GlobeNewswire · 16d ago
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Zacks · 18d ago
electroCore to Participate in Upcoming Investor Conferences
GlobeNewswire · 19d ago
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
GlobeNewswire · 23d ago
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
GlobeNewswire · 37d ago
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today
ACCESS Newswire · 60d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.